iosBio Ltd
June 16, 2025
Company Presentation
Infectious Disease and Vaccines
iosBio is developing a first-in-class Epstein-Barr virus (EBV) vaccine with the potential to revolutionize EBV prevention. Unlike current vaccine candidates that use intramuscular injection and aim to reduce disease severity, iosBio's vaccine is designed to prevent infection & transmission.
This is achieved through a combination of proprietary technologies:
• OraPro™ Oral Delivery Platform: Enables convenient oral administration, eliciting a robust mucosal immune response at the primary site of EBV infection.
• Enhance Surface Display™ Platform: Engineered for rapid onset of immunity.
• AI-Optimized Antigens: Our AI-assisted design process has produced patented antigens (including gB, gHgL, gHgL-gp42 complex, gp350) that generate class-leading antibody responses in preclinical studies.
Preclinical data demonstrate the potential of this oral EBV vaccine to provide superior protection compared to existing approaches.
We are advancing this groundbreaking vaccine into clinical development.
Company HQ City:
Haywards Heath
Company HQ State:
West Sussex
Company HQ Country:
United Kingdom
Year Founded:
2017
Lead Product in Development:
Oral Epstein-Barr virus vaccine to induce mucosal and systemic protection from infection and control of pre-existing EBV latent infection.
This is the only EBV vaccine in development that will protect from primary infection of the oral cavity as well as protection of B cells from secondary infection.
EBV market is expected to be worth $12.6bn by 2034.
CEO
Wayne M Channon
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
Commence Phase 1 and interim immunogenicity data
What is your next catalyst (value inflection) update?
September 2026
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}